...
首页> 外文期刊>癌と化学療法 >Management of nausea, vomiting and anorexia due to anticancer agents
【24h】

Management of nausea, vomiting and anorexia due to anticancer agents

机译:由于抗癌剂,恶心,呕吐和厌食的管理

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This report outlines measures for controlling nausea, vomiting, and anorexia caused by anticancer agents. Combination therapy with a 5-hydroxytryptamine (5-HT3) receptor antagonist and a steroid preparation is effective for controlling acute vomiting. In the chronic stage, however, the response to 5-HT3 receptor antagonists is less marked, so a steroid preparation is used as the major treatment in combination with a 5-HT3-receptor antagonist or metoclopramide. The antiemetic effect of recently developed tachykinin NK-1 (NK-1)-receptor antagonists has been shown to be additive to that of existing treatments for acute and chronic symptoms, especially chronic nausea/vomiting. Steroid preparations have been shown to improve anorexia, while medroxyprogesterone acetate (MPA: a synthetic progesterone) has been reported to improve anorexia and promote weight gain.
机译:本报告概述了控制恶心,呕吐和厌食的措施抗癌剂引起的。 用5-羟基三丁胺(5-HT3)受体拮抗剂和类固醇制剂的组合治疗对于控制急性呕吐是有效的。 然而,在慢性阶段,对5-HT3受体拮抗剂的反应较少标记,因此使用类固醇制剂作为与5-HT3-受体拮抗剂或甲氯普酰胺组合的主要处理。 最近开发的Tachykinin NK-1(NK-1)-receptor拮抗剂的抑制效应已被证明是对急性和慢性症状的现有治疗的添加剂,尤其是慢性恶心/呕吐。 已经显示出类固醇制剂来改善厌食症,而MEDROXYXYPTENTONE乙酸盐(MPA:合成孕酮)据报道以改善厌食并促进体重增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号